Protego Biopharma engineers first-in-class pharmacological chaperones that stabilize misfolded proteins, preventing toxic amyloid accumulation at the root of systemic amyloid diseases. Its lead candidate, PROT-001, targets immunoglobulin light chains and is being advanced toward a pivotal trial for AL amyloidosis, a rare and often fatal condition with limited treatment options. The company’s platform, grounded in human genetics and protein-folding biology, positions it to address a broad spectrum of protein misfolding disorders beyond AL amyloidosis. Protego’s approach aims to deliver disease-modifying rather than symptomatic therapies, representing a potential paradigm shift in this field. Backed by a syndicate of blue-chip life-science investors, the company is now well capitalized following its Series B raise. Although still pre-revenue, Protego benefits from renewed investor confidence and plans to use the new capital primarily for clinical development and regulatory activities related to PROT-001.

Total raised

$181M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2025